SCHEMBL1103522

SCHEMBL1103522

c1ccc2cc(-c3ccc4cc(-c5c6ccccc6c(-c6ccc7ccccc7c6)c6c5cnc5ccccc56)ccc4c3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
GPR3 P46089 1/20 0.42
CYP17A1 P05093 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
PIK3CD O00329 3/20 0.40
PIK3CA P42336 3/20 0.40
MTOR P42345 2/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
MET P08581 1/20 0.40
ESR1 P03372 3/20 0.40
ESR2 Q92731 3/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103375 1.00 KDM4E (0.42) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103452 0.98 KDM4E (0.43) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103719 0.98 KDM4E (0.43) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103519 0.97 ESR1 (0.41) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103446 0.97 ESR1 (0.43) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103356 0.96 CYP17A1 (0.41) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103385 0.96 ESR1 (0.47) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103507 0.96 CYP17A1 (0.41) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103528 0.96 ESR1 (0.43) KDM4EGPR3CYP17A1CYP19A1CYP11B1
SCHEMBL1103354 0.96 ESR1 (0.42) KDM4EGPR3CYP17A1CYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885GPR3 1503/4885CYP17A1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.